The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): Six-year long-term follow-up of a prospective, randomized phase II trial.
A. Lorch
No relevant relationships to disclose
A. Kleinhans
No relevant relationships to disclose
A. Kramar
No relevant relationships to disclose
J. T. Hartmann
No relevant relationships to disclose
C. Bokemeyer
No relevant relationships to disclose
O. Rick
No relevant relationships to disclose
J. Beyer
No relevant relationships to disclose